论文部分内容阅读
目的:观察氟伐他汀联合苯扎贝特治疗冠心病合并混合型高脂血症的调脂效果及安全性。方法:将我中心332例高脂血症患者随机分为4组,每组83例。A组口服氟伐他汀40mg.d-1,B组口服苯扎贝特400mg.d-1,C组口服氟伐他汀20mg.d-1+苯扎贝特400mg.d-1,D组口服氟伐他汀40mg.d-1+苯扎贝特400mg.d-1,4组疗程均为24周。观察患者血脂变化及不良反应等。结果:与治疗前比较,4组低密度脂蛋白胆固醇(LDL-C)均显著降低,高密度脂蛋白胆固醇(HDL-C)显著上升(P<0.05),且治疗后A、C、D组LDL-C显著优于B组(P<0.001),B、C、D组HDL-C显著优于A组(P<0.001)。其中,D组各项指标治疗效果最佳。4组患者均具有较好的耐受性,均未见严重不良反应发生。结论:氟伐他汀40mg联合苯扎贝特400mg治疗混合型高脂血症疗效较好,能有效纠正各项临床指标,具有较好的安全性和耐受性。
Objective: To observe the effect and safety of fluvastatin combined with bezafibrate in the treatment of coronary heart disease complicated with mixed hyperlipidemia. Methods: 332 cases of hyperlipidemia in our center were randomly divided into 4 groups, 83 cases in each group. A group of oral fluvastatin 40mg.d-1, B group oral bezafibrate 400mg.d-1, C group oral fluvastatin 20mg.d-1 + bezafibrate 400mg.d-1, D group oral Fluvastatin 40mg.d-1 + bezafibrate 400mg.d-1,4 treatment group were 24 weeks. Observe the changes of blood lipids and adverse reactions in patients. Results: Compared with those before treatment, the levels of LDL-C and HDL-C in 4 groups were significantly decreased (P <0.05), and the levels of HDL-C in groups A, LDL-C was significantly better than that of group B (P <0.001), HDL-C of group B, C and D was significantly better than that of group A (P <0.001). Among them, the D group of indicators of the best treatment. All 4 patients had good tolerance, and no serious adverse reactions occurred. Conclusion: Fluvastatin 40mg combined with bezafibrate 400mg has good curative effect on mixed hyperlipidemia, which can effectively correct various clinical indexes and has good safety and tolerability.